Shares in Dunedin cancer diagnostic company Pacific Edge have
taken off again on the back of positive news from the United
Since Pacific Edge announced on Thursday the granting of US
patent protection over a new melanoma development, its shares
have risen from 80c to trade around 95c yesterday, closing at
94c. Pacific Edge became one of the stock exchange's top
performers last year.
Following a deluge of announcements of new contracts last
year, the company's shares rose from 45c to hit $1.74 over 12
weeks, before trailing off to 65c recently.